Published online before print October 13, 2005, doi: 10.1161/01.ATV.0000190701.92007.6d
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 American Heart Association, Inc.
Vascular Biology |
Novel Autologous Cell Therapy in Ischemic Limb Disease Through Growth Factor Secretion by Cultured Adipose Tissue–Derived Stromal Cells
From the Division of Gene Therapy Science (H.N., S.I., T.N., Y.T., Y.K., Y.S., K.T., Y.K.), Graduate School of Medicine, Osaka University; the Medical Center for Translational Research (H.N., K.M.), Osaka University Hospital; the Division of Clinical Gene Therapy (R.M.), Graduate School of Medicine, Osaka University; and the Department of Geriatric Medicine (Y.T., T.O.), Graduate School of Medicine, Osaka University, Osaka, Japan
Correspondence to Dr Hironori Nakagami, Department of Gene Therapy Science, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita 565-0871, Japan. E-mail nakagami{at}gts.med.osaka-u.ac.jp
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Objective— The delivery of autologous progenitor cells into ischemic tissue of patients is emerging as a novel therapeutic option. Here, we report the potential impact of cultured adipose tissue–derived cells (ADSC) on angiogenic cell therapy.
Method and Results— ADSC were isolated from C57Bl/6 mouse inguinal adipose tissue and showed high expression of ScaI and CD44, but not c-kit, Lin, CD34, CD45, CD11b, and CD31, compatible with that of mesenchymal stem cells from bone marrow. In coculture conditions with ADSC and human aortic endothelial cells (ECs) under treatment with growth factors, ADSC significantly increased EC viability, migration and tube formation mainly through secretion of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF). At 4 weeks after transplantation of ADSC into the ischemic mouse hindlimb, the angiogenic scores were improved in the ADSC-treated group, which were evaluated with blood flow by laser Doppler imaging (LDI) and capillary density by immunostaining with anti-CD31 antibody. However, injected ADSC did not correspond to CD31, von Willebrand factor, and 
-smooth muscle actin-positive cells in ischemic tissue.
Conclusion— These adipose tissue–derived cells demonstrated potential as angiogenic cell therapy for ischemic disease, which appears to be mainly achieved by their ability to secrete angiogenic growth factors.
The adipose tissue–derived cells (ADSCs) induced angiogenesis through secretion of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in coculture with endothelial cells or ischemic mouse hindlimb model. These results demonstrated the potential of ADSC as angiogenic cell therapy for ischemic disease.
Key Words: adipose tissue • angiogenesis • growth factors • HGF • VEGF
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Therapeutic angiogenesis, a strategy to treat tissue ischemia by promoting the proliferation of collateral vessels, has emerged as one of the most promising therapies developed to date.1,2 Therapeutic potential of various angiogenic molecules has been reported in animal models or humans with ischemic disease.3,4 Recently, autologous transplantation of bone marrow (BM) stromal cells or endothelial cell (EC) progenitors has been shown to enhance angiogenesis or peripheral blood flow, and these cells were incorporated into sites of angiogenesis after tissue ischemia in the limb, retina, and myocardium.5–7 However, it has also been suggested that bone marrow mononuclear cells contain various characteristics of stem cells for mesenchymal tissues8 and secrete a broad spectrum of angiogenic or antiangiogenic cytokines, such as IL-1ß, which would play a role in the process of angiogenesis.9
Adipose tissue, like bone marrow, is derived from the embryonic mesenchyme and contains stroma that is easily isolated,10 which was classically used to investigate pre-adipocyte differentiation into mature adipocytes. However, this fraction was also reported to be a very convenient and nonrestrictive source of pluripotent cells such as hematopoietic progenitors and spare mesodermal stem cells able to differentiate into osteogenic, chondrogenic, myogenic, and neurogenic lineages.11,12 Moreover, in rodents, the presence of hematopoietic stem cells in adipose tissue–derived stromal cells (ADSCs) has been suggested, and the presence of a cell population expressing the stem cell marker CD34 has been shown in ADSC from human adipose tissue.13 These cells could differentiate into endothelial cells and participate in vessel formation, and interestingly, administration of adipose tissue–derived cells could potentially affect revascularization to a similar degree to BM-MNC administration.14 Of importance, ADSC secrete multiple angiogenic growth factors, such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), at levels that are bioactive.15,16 However, how to use the advantage of "cultured ADSC" for angiogenic therapy still needs to be determined.
In this study, we developed cultured ADSC from mouse inguinal fat, which showed fairly homogeneous characteristics compatible with mesenchymal stem cells. ADSC can differentiate into endothelial cells and secrete angiogenic growth factors that strongly induce endothelial cell growth, migration, and tube formation. Transplantation of these cultured ADSC to ischemic limbs accelerated angiogenesis mainly caused by secretion of growth factors, rather than participation in vessel formation by differentiation.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Cell Culture
ADSCs were isolated from adipose tissue according to the method of Bjorntorp et al with minor modification.17 Human aortic endothelial cells and aortic smooth muscle cells (passage 3) were obtained from Clonetics Corp (San Diego, Calif), and cultured in modified MCDB131 medium (EGM2-MV; Clonetics Corp) or smooth muscle medium supplemented with 5% fetal bovine serum and smooth muscle growth supplement (Clonetics Corp) in the standard fashion.18 Detail information is described in Supplement (http://atvb.ahajournals.org).
Fluorescence-Activated Cell Sorting and Immunostaining
A total of 2x105 cells were resuspended in 200 µL phosphate-buffered saline containing 3% bovine serum albumin and incubated for 30 minutes with fluorescence-labeled antibodies against Ly-6A/E (ScaI)-PE (phycoerythrin), CD117 (c-kit)-fluorescein isothiocyanate (FITC) (FITC), CD31-PE, CD34-PE, CD45-PE, CD11b-PE, CD44-PE, or the respective isotype control, which were obtained from BD Biosciences (Franklin Lakes, NJ). Cells were also incubated with biotin-conjugated mouse lineage panel antibodies against CD3e, CD11b, Ly-6G and -6C, Ter-119, and CD45R/B220 (Lyn; BD Biosciences) and further incubated with streptavidin-PE. After washing steps, the labeled cells were analyzed in 3 channels: FITC in FL1, orange fluorescence (PE) in FL2, and long-wavelength red fluorescence in FL3 by flow cytometry by means of a fluorescence-activated-cell sorter (FACS) Calibur flow cytometer and CellQuest Pro software (BD Biosciences).
To immunostain cells for platelet/endothelial cell adhesion molecule 1 (PECAM) (CD31) or VE-cadherin, cells were fixed for 30 minutes at room temperature with methanol, and permeabilized for 5 minutes with 0.2% Triton X-100 and 1% goat serum. They were then incubated with an antibody to PECAM or VE-cadherin (1:100, Pharmingen, San Diego, Calif) and further incubated with Alexa Fluor 488 anti-rat antibody (1:200, Molecular Probes, Inc., Eugene, OR).
Cell Viability, Migration, and Tube Formation Assay
Cell viability of HAEC was measured by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay (CellTiter 96, Promega, Madison, Wis) as previously described.18 Migration of HAECs was estimated in a modified Boyden chamber as previously described.19 An angiogenesis kit (Kurabo, Tokyo, Japan) was used for tube formation assay as described by the manufacturer. The detail information was described in Supplement.
Reverse Transcription-Polymerase Chain Reaction Analysis
The conditions of the polymerase chain reaction (PCR) and design of oligonucleotide primers followed a previous report20 with minor modification. We performed quantitative real-time PCR analysis. The detail information about reverse-transcription PCR is described in the Supplement.
Mouse Hindlimb Ischemic Model and Evaluation of Angiogenesis
Wild-type C57BL/6J mice were anesthetized with ketamine chloride (80 mg/kg) and xylidine sulfate (8 mg/kg) subcutaneously, and unilateral hindlimb ischemia was induced as described previously.21 Blood flow by laser Doppler imaging (LDI) (Moor Instruments, Devon, United Kingdom) and capillary density within the ischemic thigh adductor skeletal muscles was performed for analysis of angiogenesis as described previously22 All experimental protocols were approved by the Osaka University Graduate School of Medicine Standing Committee on Animals. Detailed methods are described in the Supplement.
Statistical Analysis
All values were expressed as mean±SEM. Analysis of variance with subsequent Bonferroni’s/Dunnet’s test was used to determine the significance of differences in multiple comparisons. Values of P<0.05 were considered statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Pluripotency of ADSCs
The inguinal fat pads from each mouse yielded approximately 1x105 nucleated cells. Freshly isolated ADSC showed adherence and expansion in culture. After second passage of cell expansion, FACS analysis of cultured ADSC indicated that ScaI and CD44 antigen were expressed, but not c-kit, Lin, CD11b, CD31, CD34, or CD45 (Figure 1A). This suggests that ADSC include a large population of mesenchymal stem cells, but no hematopoietic stem cells.23 Of importance, these characteristics of ADSC surface markers were conserved after several passages of cell expansion. These cells look like fibroblasts and can differentiate into not only adipocytes but also chondrogenic and osteogenic lineages in vitro as previous described.12 To examine the pluripotency of ADSC, we tried to induce them to differentiate toward endothelial cells. Because murine embryonic stem cells or human endothelial progenitor cells can differentiate into endothelial cells with growth factor-rich medium in collagen-coated dishes,24 we seeded ADSC into collagen I-coated dishes with DMEM or growth factor-rich EGM2-MV medium for 5 days. Although PECAM-positive or VE-cadherin positive cells were not observed in ADSC cultured in EBM-2 medium, we found a few PECAM-positive or VE-cadherin-positive cells in growth factor-rich medium, which showed a spindle shape similar to endothelial progenitor cells from bone marrow (Figure I, available online at http://atvb.ahajournals.org). To further confirm the differentiation of ADSC into EC, we also followed Flk-1, Tie-2, and PECAM gene expression by reverse-transcription PCR. After differentiation of murine ADSC in growth factor-rich EGM medium, we collected the PECAM-positive endothelial cells from ADSC using mouse specific anti-PECAM antibody-attached magnet beads and extracted mRNA from them as differentiated EC. As shown in Figure 1B, we confirmed the mRNA expression of Flk-1, Tie-2, and PECAM only in differentiated EC.
|
Effects of ADSC on EC Viability, Migration, and Tube Formation
Increasing numbers of reports highlight the possibility that adipogenesis and neovascularization are reciprocally regulated and tightly linked in rodents.25,26 Because the proliferation and migration of endothelial cells are important aspects of angiogenesis, we examined the effect of ADSC-conditioned medium in a coculture system of human aortic endothelial cells. Cell viability of endothelial cells in the conditioned medium from ADSC was significantly higher than that in conditioned medium from EC, and the conditioned medium from ADSC in growth factor-rich EGM2-MV medium resulted in an even greater increase in viability, assessed by MTS assay (Figure 2A). In migration assay of EC, conditioned medium from ADSC in growth factor-rich EGM2-MV medium resulted in a significant increase in viability, to a lesser extent in growth factor-withdrawal EGM2-MV medium, compared with conditioned medium from EC in EGM2-MV medium (Figure 2B). In tube formation assay, conditioned medium from ADSC in EGM2-MV medium also showed a significant increase in several parameters (length, area, joint, path) compared with the conditioned medium from EC in EGM2-MV medium (Figure 2C).
|
P<0.01 vs ADSC (EGM).
Secretion of Angiogenesis-Related Cytokines From ADSC
It is known that ADSC secrete multiple angiogenic growth factors, such as VEGF and HGF, at levels that are bioactive.15,16 We quantified the expression level of angiogenesis-related cytokines by real time PCR from human ADSC and vascular smooth muscle cells (VSMCs). As shown in Figure 3A, we observed the relatively high expression of HGF, VEGF, placental growth factor (PGF), and transforming growth factor (TGF)-ß, the moderate expression of fibroblast growth factor (FGF)-2 and angiopoietin (Ang)-1, and the low level of Ang-2 from ADSC, and the expression level of HGF and VEGF were markedly higher than that of VSMC. In the analysis of enzyme-linked immunoassay, ADSC secreted a significant amount of HGF, and to a lesser extent VEGF, in EBM-2 medium for 72 hours. When ADSC were cultured in growth factor-rich EGM2-MV medium, consistent and prominent augmentation of both HGF and VEGF secretion was observed (Figure II, available online at http://atvb.ahajournals.org). To examine the effects of these growth factors on EC viability and migration, we used VEGF and HGF neutralizing polyclonal antibodies in a human ADSC and EC coculture system. We used human ADSC from human adipose tissue only in these experiments. Because anti-murine HGF neutralizing antibody is not available and anti-VEGF neutralizing antibody cross-reacts with both murine and human VEGF, it is better to use human cells to compare the contribution of these growth factors. Treatment with anti-HGF neutralizing antibody (10 µg/mL) in conditioned medium from ADSC resulted in 
25% inhibition of EC viability (MTS assay) and 48% inhibition of EC migration, and treatment with anti-VEGF neutralizing antibody (10 µg/mL) resulted in 23% inhibition of EC viability and 26% inhibition of EC migration. The both treatments with these 2 antibodies could return the EC viability and migration to the baseline level. (Figure 3B). These results suggest that these 2 growth factors have a great contribution to EC viability and migration induced by conditioned medium from ADSC.
|
Angiogenic Effect of ADSC in Mice Ischemic Hindlimb Model
To determine whether transplantation of ADSC could induce an angiogenic effect, we evaluated the angiogenic effect of injected murine ADSC in the mouse ischemic limb. At 10 days after unilateral ligation of femoral artery of the mouse hindlimb, we performed LDI and separated the mice into three groups: injection of PBS or 1x106 ADSC cultured with growth factor-rich or withdrawal EGM2-MV medium. Figure 4A shows representative LDI images of hindlimb blood flow at 14 and 28 days after transplantation. Although serial LDI examination disclosed natural recovery of hindlimb blood flow in the control group, transplantation of ADSC resulted in more rapid recovery of the ratio of ischemic/normal blood flow. Interestingly, transplantation of ADSC in growth factor-rich EGM2-MV medium further improved it.
|
To investigate the degree of angiogenesis at the microcirculation level, we measured capillary density in histological sections harvested from the ischemic tissues. The representative photomicrographs of tissue immunostained with anti-CD31 antibody were shown in Figure III (available online at http://atvb.ahajournals.org). Quantitative analysis revealed that the capillary density was significantly increased by ADSC in growth factor-rich EGM2-MV medium, and to a lesser extent by ADSC in growth factor-withdrawal EGM2-MV medium, compared with the control group (Figure 4B).
We further performed the comparative study with bone marrow nuclear cells (BMN) and HGF gene therapy that had been already performed in human clinical trial for peripheral arterial diseases.4,7 In the analysis of blood flow by LDI at 28 days after each treatment, there was no significant difference between three groups (Figure III).
Involvement of ADSC in Vasculogenesis
To confirm whether ADSC are directly involved in the development of vasculogenesis in the ischemic limb, we isolated ADSC from mice engineered to constitutively express GFP and injected ADSC cultured in EGM2-MV medium into the mouse ischemic limb as described. At 3, 14, or 28 days after injection, we isolated muscle and observed GFP-positive cells. As shown in Figure 5, we identified a few clusters of GFP-positive cells in the ischemic area, which may have been the injected area, at 3 days after cell transplantation, and fewer GFP-positive cells at 14 days, and almost no GFP-positive cells by immunostaining with anti-GFP antibody at 28 days, which did not correspond to the distribution of CD31, von Willebrand factor and -smooth muscle actin-positive cells. It suggests that ADSC might be not directly involved in the development of vasculogenesis in this model.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The present study demonstrated that transplantation of ADSC induced angiogenesis accompanied by an increase of blood flow and capillary density in the ischemic limb.
Despite the promising potential for regenerative applications, the fundamental scarcity of endothelial progenitor cell populations in the hematopoietic system constitutes an important limitation of primary endothelial progenitor cell transplantation. It was reported that ex vivo expansion of endothelial progenitor cells cultured from the peripheral blood of healthy human volunteers yielded 5.0x106 cells per 100 mL of blood, whereas heterologous transplantation requires 0.5 to 2.0x104 human endothelial progenitor cells per gram of body weight (of the recipient mouse) to achieve satisfactory reperfusion of the ischemic hindlimb.27 Actually, the amount of autologous BM blood aspirated for therapeutic neovascularization was approximately 500 mL per person (ie, 0.1% of body weight).7 This suggests a practical limitation of endothelial progenitor cell transplantation; namely, the volume of blood required to extract an adequate number of endothelial progenitor cells for autologous transplantation. The main benefit of our ADSC is that they can be easily harvested from patients by a simple, minimally invasive method and also easily cultured (1x105 cells from one mouse and 20 mL lipoaspiration from a human). Moreover, cultured ADSC can be expanded more rapidly (>10 times within 1 week), and long-term cultured cells after some passages still retain their mesenchymal pluripotency, with expression of ScaI and CD44. This suggests that ADSC could be a good candidate as a novel source of cell therapy in cardiovascular disease.
Recently, therapeutic endothelial stem cell transplantation was suggested to be a promising approach to restore tissue vascularization after ischemic events.6 However, the true in vivo differentiation capacity of adult BM stem and progenitor cells and their possible contribution to nonhematopoietic cells and tissues including endothelial cells remain controversial.28,29 We speculate that the injection of cells are not mimicking strictly the natural course of the cells infused or the cultured stem cells under special conditions can change the properties of these cells in terms of their capacity to incorporate into target tissue. In addition, we have to observe carefully whether the survive cells would be a "differentiation" or "fusion." A very recent report suggested that adult BM-derived cells participate in angiogenesis, and a small subpopulation of them differentiate into vascular mural peri-endothelial cells that are morphologically indistinguishable from pericytes.30 BM contains nonhematopoietic stromal cells, which comprise immature mesenchymal stem cells, EPC, fibroblasts, osteoblasts, EC, and adipocytes,8 and infiltrating inflammatory leukocytes release angiogenic cytokines including VEGF. Interestingly, treatment with anti-VEGF monoclonal antibody completely abolished BM-induced neovascularization.31 This suggests that stem cell transplantation is also "cell-based cytokine therapy." Of importance, in this study we used media containing growth factors to induce the direction of differentiation into vascular cells, to avoid differentiation into unexpected cells, and also activate the secretion of angiogenic growth factors leading to "cell-based cytokine therapy." Although in this study our ADSC-mediated cell therapy did not show further angiogenic effect in the comparison with BM cell or HGF gene therapy, it would be a study limitation to conclude their effectiveness in this ischemic hindlimb model. Our cultured ADSC can provide stem cells by FACS analysis and are easily available for autologous cell therapy, which would allow feasible implementation of "stem cell-based functional gene therapy" in the future.
Increasing numbers of reports highlight the possibility that adipogenesis and neovascularization are reciprocally regulated and tightly linked in rodents. Our results indicate that ADSC represent an easily accessible cell source with potential effects that can be used for therapeutic angiogenesis through growth factor secretion, so-called adipocytokine.
|
Acknowledgments |
|---|
This work was partially supported by grants from Takeda Foundation and from the grant-in-aid from The Ministry of Education, Science, Sports, and Culture of Japan. We thank K. Mori for his excellent technical assistance and Dr M. Okabe for providing GFP transgenic mice.
Received March 27, 2005; accepted September 7, 2005.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9: 653–660.[CrossRef][Medline] [Order article via Infotrieve]
2. Freedman SB, Isner JM. Therapeutic angiogenesis for ischemic cardiovascular disease. J Mol Cell Cardiol. 2001; 33: 379–393.[CrossRef][Medline] [Order article via Infotrieve]
3. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med. 2002; 136: 54–71.
4. Morishita R, Aoki M, Hashiya N, Makino H, Yamasaki K, Azuma J, Sawa Y, Matsuda H, Kaneda Y, Ogihara T. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension. 2004; 44: 203–209.
5. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, Silver M, Ma H, Kearney M, Isner JM, Asahara T. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 2001; 103: 634–637.
6. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003; 9: 702–712.[CrossRef][Medline] [Order article via Infotrieve]
7. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002; 360: 427–435.[CrossRef][Medline] [Order article via Infotrieve]
8. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997; 276: 71–74.
9. Maruyama K, Mori Y, Murasawa S, Masaki H, Takahashi N, Tsutusmi Y, Moriguchi Y, Shibazaki Y, Tanaka Y, Shibuya M, Inada M, Matsubara H, Iwasaka T. Interleukin-1 beta upregulates cardiac expression of vascular endothelial growth factor and its receptor KDR/flk-1 via activation of protein tyrosine kinases. J Mol Cell Cardiol. 1999; 31: 607–617.[CrossRef][Medline] [Order article via Infotrieve]
10. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001; 7: 211–228.[CrossRef][Medline] [Order article via Infotrieve]
11. Tholpady SS, Katz AJ, Ogle RC Mesenchymal stem cells from rat visceral fat exhibit multipotential differentiation in vitro. Anat Rec. 2003; 272A: 398–402.[CrossRef][Medline] [Order article via Infotrieve]
12. Ogawa R, Mizuno H, Watanabe A, Migita M, Shimada T, Hyakusoku H. Osteogenic and chondrogenic differentiation by adipose-derived stem cells harvested from GFP transgenic mice. Biochem Biophys Res Commun. 2004; 313: 871–877.[CrossRef][Medline] [Order article via Infotrieve]
13. Miranville A, Heeschen C, Sengenes C, Curat CA, Busse R, Bouloumie A. Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation. 2004; 110: 349–355.
14. Planat-Benard V, Silvestre JS, Cousin B, Andre M, Nibbelink M, Tamarat R, Clergue M, Manneville C, Saillan-Barreau C, Duriez M, Tedgui A, Levy B, Penicaud L, Casteilla L. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation. 2004; 109: 656–663.
15. Rehman J, Considine RV, Bovenkerk JE, Li J, Slavens CA, Jones RM, March KL. Obesity is associated with increased levels of circulating hepatocyte growth factor. J Am Coll Cardiol. 2003; 41: 1408–1413.
16. Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, Pell CL, Johnstone BH, Considine RV, March KL. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation. 2004; 109: 1292–1298.
17. Bjorntorp P, Karlsson M, Pertoft H, Pettersson P, Sjostrom L, Smith U. Isolation and characterization of cells from rat adipose tissue developing into adipocytes. J Lipid Res. 1978; 19: 316–324.[Abstract]
18. Nakagami H, Morishita R, Yamamoto K, Taniyama Y, Aoki M, Matsumoto K, Nakamura T, Kaneda Y, Horiuchi M, Ogihara T. Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension. 2001; 37: 581–586.
19. Rikitake Y, Hirata K, Kawashima S, Ozaki M, Takahashi T, Ogawa W, Inoue N, Yokoyama M. Involvement of endothelial nitric oxide in sphingosine-1-phosphate-induced angiogenesis. Arterioscler Thromb Vasc Biol. 2002; 22: 108–114.
20. Vittet D, Prandini MH, Berthier R, Schweitzer A, Martin-Sisteron H, Uzan G, Dejana E. Embryonic stem cells differentiate in vitro to endothelial cells through successive maturation steps. Blood. 1996; 88: 3424–3431.
21. Sata M, Nishimatsu H, Suzuki E, Sugiura S, Yoshizumi M, Ouchi Y, Hirata Y, Nagai R. Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia. FASEB J. 2001; 15: 2530–2532.
22. Taniyama Y, Morishita R, Aoki M, Nakagami H, Yamamoto K, Yamazaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther. 2001; 8: 181–189.[CrossRef][Medline] [Order article via Infotrieve]
23. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood. 2004; 103: 1662–1668.
24. Yamashita J, Itoh H, Hirashima M, Ogawa M, Nishikawa S, Yurugi T, Naito M, Nakao K. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature. 2000; 408: 92–96.[CrossRef][Medline] [Order article via Infotrieve]
25. Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, Folkman MJ. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A. 2002; 99: 10730–10735.
26. Fukumura D, Ushiyama A, Duda DG, Xu L, Tam J, Krishna V, Chatterjee K, Garkavtsev I, Jain RK. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ Res. 2003; 93: e88–97.
27. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000; 97: 3422–3427.
28. Ziegelhoeffer T, Fernandez B, Kostin S, Heil M, Voswinckel R, Helisch A, Schaper W. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res. 2004; 94: 230–238.
29. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science. 2002; 297: 2256–2259.
30. Rajantie I, Ilmonen M, Alminaite A, Ozerdem U, Alitalo K, Salven P. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood. 2004; 104: 2084–2086.
31. Sasaki K, Murohara T, Ikeda H, Sugaya T, Shimada T, Shintani S, Imaizumi T. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest. 2002; 109: 603–611.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  R. Madonna, Y.-J. Geng, and R. De Caterina Adipose Tissue-Derived Stem Cells: Characterization and Potential for Cardiovascular Repair Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1723 - 1729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Seeger, T. Rasper, M. Koyanagi, H. Fox, A. M. Zeiher, and S. Dimmeler CXCR4 Expression Determines Functional Activity of Bone Marrow-Derived Mononuclear Cells for Therapeutic Neovascularization in Acute Ischemia Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1802 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. O. Traktuev, D. N. Prater, S. Merfeld-Clauss, A. R. Sanjeevaiah, M. R. Saadatzadeh, M. Murphy, B. H. Johnstone, D. A. Ingram, and K. L. March Robust Functional Vascular Network Formation In Vivo by Cooperation of Adipose Progenitor and Endothelial Cells Circ. Res., June 19, 2009; 104(12): 1410 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kondo, S. Shintani, R. Shibata, H. Murakami, R. Murakami, M. Imaizumi, Y. Kitagawa, and T. Murohara Implantation of Adipose-Derived Regenerative Cells Enhances Ischemia-Induced Angiogenesis Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 61 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Madonna and R. De Caterina In vitro neovasculogenic potential of resident adipose tissue precursors Am J Physiol Cell Physiol, November 1, 2008; 295(5): C1271 - C1280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. O. Traktuev, S. Merfeld-Clauss, J. Li, M. Kolonin, W. Arap, R. Pasqualini, B. H. Johnstone, and K. L. March A Population of Multipotent CD34-Positive Adipose Stromal Cells Share Pericyte and Mesenchymal Surface Markers, Reside in a Periendothelial Location, and Stabilize Endothelial Networks Circ. Res., January 4, 2008; 102(1): 77 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-W. Cho, S.-H. Moon, S.-H. Lee, S.-W. Kang, J. Kim, J. M. Lim, H.-S. Kim, B.-S. Kim, and H. M. Chung Improvement of Postnatal Neovascularization by Human Embryonic Stem Cell-Derived Endothelial-Like Cell Transplantation in a Mouse Model of Hindlimb Ischemia Circulation, November 20, 2007; 116(21): 2409 - 2419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Sze, D. P. V. de Kleijn, R. C. Lai, E. Khia Way Tan, H. Zhao, K. S. Yeo, T. Y. Low, Q. Lian, C. N. Lee, W. Mitchell, et al. Elucidating the Secretion Proteome of Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Mol. Cell. Proteomics, October 1, 2007; 6(10): 1680 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Gimble, A. J. Katz, and B. A. Bunnell Adipose-Derived Stem Cells for Regenerative Medicine Circ. Res., May 11, 2007; 100(9): 1249 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Saito, H. Nakagami, R. Morishita, Y. Takami, Y. Kikuchi, H. Hayashi, T. Nishikawa, K. Tamai, N. Azuma, T. Sasajima, et al. Transfection of Human Hepatocyte Growth Factor Gene Ameliorates Secondary Lymphedema via Promotion of Lymphangiogenesis Circulation, September 12, 2006; 114(11): 1177 - 1184. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||